Salute e Benessere
CABLIVI Market Reports Positive Growth - Strong Momentum Expected to Continue | DelveInsight
CABLIVI is an antibody fragment that targets von Willebrand factor (vWF) and is used to treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy. It works by binding to the A1-domain of vWF, preventing its interaction with platelets, which helps reduce vWF-mediated platelet adhesion and consumption. CABLIVI is approved in both the US and EU for treating aTTP. In 2024, CABLIVI sales reached , reflecting a increase, driven by a rise in the number of patients identified for suitable treatment in the US, as well as new launches in Europe and other regions.
The recommended CABLIVI dosing schedule is as follows:
Administer an 11 mg intravenous bolus injection at least 15 minutes before plasma exchange, followed by an 11 mg subcutaneous injection after the exchange on the same day.
Administer 11 mg subcutaneously once daily after each plasma exchange session.
Continue with 11 mg subcutaneous injections once daily for 30 days after the final plasma exchange. If signs of persistent underlying disease, such as low ADAMTS13 activity, are still present, treatment can be extended for up to 28 additional days.
CABLIVI treatment should be discontinued if the patient experiences more than two recurrences of aTTP while on the medication.
Learn more about CABLIVI projected market size for thrombocytopenia @
Thrombocytopenia is a medical condition where the platelet count in the blood drops below the normal level (<150,000/µL). Common causes include heparin-induced thrombocytopenia, chemotherapy-induced thrombocytopenia, thrombocytopenia linked to chronic liver disease, immune thrombocytopenia (ITP), and thrombotic thrombocytopenic purpura (TTP). Among the 7MM, the United States reported the highest number of thrombocytopenia cases, accounting for about of the total cases in 2023, according to DelveInsight.
Treatment for thrombocytopenia varies based on its cause and severity, with the primary goal of preventing bleeding-related complications and improving patient outcomes. Approved therapies for thrombocytopenia in the US include . Additionally, danaparoid, argatroban, and lepirudin are approved for treating thrombosis in patients with heparin-induced thrombocytopenia.
For severe thrombocytopenia related to chronic liver disease, treatment options include platelet transfusion, splenic artery embolization, splenectomy, and transjugular intrahepatic portosystemic stent shunt (TIPSS) placement.
The US holds approximately of the thrombocytopenia market share, surpassing the combined market size of the EU4, the UK, and Japan . Market growth is expected to be driven by an increasing patient population, the introduction of new therapies, and deeper market penetration within the 7MM.
Discover more about the thrombocytopenia market in detail @
The potential therapies that can mark a significant change in the thrombocytopenia treatment landscape and give tough competition to CABLIVI include (Sanofi), (Novartis), (Takeda), (Pfizer), (Vertex), (Genosco/Oscotec), and (ARGX-113) (Argenx), among others.
In shared encouraging Phase III results at ASH for , its investigational oral BTK inhibitor, in patients with ITP. In reported late-breaking Phase IIb data on , highlighting its potential to revolutionize the treatment of Primary ITP.
In , the company forecasted key trial results: for first-line therapy, expected in 2026, and for second-line therapy, anticipated in 2025. Novartis also aims to file for ianalumabin approval in both first- and second-line ITP treatment by 2027 or later.
To know more about the number of competing drugs in development, visit @
Discover how CABLIVI is shaping the thrombocytopenia treatment landscape @
The primary driver of CABLIVI's market growth is the , coupled with improved access to specialized treatments. among healthcare providers and advancements in diagnostic capabilities have facilitated early and accurate diagnosis, thereby boosting the . The drug's ability to has positioned it as a preferred option in the treatment landscape for aTTP. Moreover, have further contributed to market penetration and adoption.
Despite its therapeutic benefits, CABLIVI faces challenges related to its . The specialized nature of aTTP treatment, combined with the requirement for hospital-based administration and close monitoring, adds to the overall . Additionally, , including plasma exchange and immunosuppressive treatments, may limit its market expansion. Regulatory hurdles and the need for long-term safety data could also impact the drug's market trajectory.
The CABLIVI market is expected to grow steadily, driven by into related thrombotic disorders. in rare disease treatments and orphan drug incentives are likely to support market growth. Moreover, the to improve patient access and streamline reimbursement processes could enhance market uptake. However, will remain a key factor in sustaining long-term market performance.
Dive deeper to get more insight into CABLIVI's strengths & weaknesses relative to competitors @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acquired thrombotic thrombocytopenic purpura companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key thrombocytopenia companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key thrombocytopenia companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key immune thrombocytopenia companies including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cablivi-market-reports-positive-growth--strong-momentum-expected-to-continue--delveinsight-302405389.html